Phase 3
N=10,160
Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in Adults
Virus Diseases · RNA Virus Infections · Respiratory Tract Diseases · Respiratory Tract Infections · Influenza
Bottom Line
View on ClinicalTrials.gov: NCT03301051 ↗Enrolled (actual)
10,160
Serious AEs
1.1%
Results posted
Aug 2023
Primary outcome: Primary: Number of Occurrences of Protocol-Defined Respiratory Illness Caused by Vaccine-Matched Influenza Strains — 110; 169 Number of cases
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- Quadrivalent VLP Vaccine (Biological); Placebo (Biological)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Medicago
- Primary completion
- May 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Occurrences of Protocol-Defined Respiratory Illness Caused by Vaccine-Matched Influenza Strains |
110; 169 | — |
| SECONDARY Number of Occurrences of Protocol-Defined Respiratory Illness Cases Caused by Any Laboratory Confirmed Influenza Strain |
213; 347 | — |
| SECONDARY Number of Occurrences of Laboratory-Confirmed Protocol-Defined Influenza-Like Illness (ILI) Caused by Vaccine-Matched Influenza Strains |
98; 148 | — |
| SECONDARY Number of Occurrences of Laboratory-Confirmed ILI Caused by Any Influenza Strain |
178; 285 | — |
| SECONDARY Number of Occurrences of Protocol-Defined ILI Cases |
1576; 1679 | — |
| SECONDARY Number of Participants With at Least One Immediate Complaint |
441; 377 | — |
| SECONDARY Number of Participants With at Least One Solicited Local and Systemic Reactions |
2776; 1723 | — |
| SECONDARY Number of Participants With ≥ Severe Solicited Local and Systemic Reactions |
75; 85 | — |
| SECONDARY Number of Participants With ≥ Severe Related Solicited Reactions |
56; 62 | — |
| SECONDARY Number of Participants With Unsolicited Treatment-Emergent Adverse Events (TEAEs) |
661; 639 | — |
| SECONDARY Number of Participants With ≥ Severe Unsolicited TEAEs |
13; 25 | — |
| SECONDARY Number of Participants With ≥ Severe Related Unsolicited Reactions |
4; 6 | — |
| SECONDARY Number of Participants With an Occurrence of Death |
1; 2 | — |
| SECONDARY Number of Participants With at Least One Serious TEAE |
55; 51 | — |
| SECONDARY Number of Participants With at Least One AE Leading to Withdrawal |
0; 5 | — |
| SECONDARY Number of Participants With at Least One New Onset Chronic Diseases (NOCDs) |
54; 41 | — |
| SECONDARY Geometric Mean Titers (GMTs) of Hemagglutination Inhibition (HI) Antibody Response for Each Homologous and Heterologous Influenza Strain |
24.2; 30.0; 84.8; 27.8; 26.2; 29.0 | — |
| SECONDARY Percentage of Participants With Seroconversion Measured by HI Antibody Response for Each Homologous and Heterologous Strain |
37.1; 0; 46.4; 0; 17.6; 0 | — |
| SECONDARY Percentage of Participants With Seroprotection Measured by HI Antibody Response for Each Homologous and Heterologous Strain |
40.6; 47.4; 74.8; 39.2; 46.4; 46.4 | — |
| SECONDARY Geometric Mean Fold Ratio (GMFR) of HI Antibody Response for Each Homologous and Heterologous Strain |
3.4; 1.0; 5.5; 1.0; 2.2; 0.9 | — |
| SECONDARY GMTs of Microneutralization (MN) Antibody Response for Each Homologous Strain |
88.1; 112.3; 366.1; 135.7; 46.7; 62.1 | — |
| SECONDARY Percentage of Participants With Seroconversion Measured by MN Antibody Response for Each Homologous Strain |
41.7; 2.1; 28.1; 0; 30.6; 0 | — |
| SECONDARY GMFR of MN Antibody Response for Each Homologous Strain |
4.0; 1.3; 2.5; 1.2; 2.5; 1.1 | — |
| SECONDARY Geometric Mean Area (GMA) of Single Radial Hemolysis (SRH) Antibody Response for Each Homologous Strain |
10.3; 15.4; 31.4; 20.9; 15.6; 19.3 | — |
| SECONDARY Percentage of Participants With Seroconversion Measured by SRH Antibody Response for Each Homologous Strain |
53.6; 14.4; 48.2; 14.4; 45.7; 9.3 | — |
| SECONDARY Percentage of Participants With Seroprotection Measured by SRH Antibody Response for Each Homologous Strain |
36.3; 42.3; 75.9; 57.7; 54.7; 57.7 | — |
| SECONDARY GMFR of SRH Antibody Response for Each Homologous Strain |
2.9; 1.6; 3.5; 1.6; 4.0; 1.3 | — |
Summary
This Phase 3 study is intended to assess the efficacy of the Quadrivalent VLP Influenza Vaccine during the 2017-2018 influenza season in healthy adults 18 to 64 years of age. One dose of Quadrivalent VLP Influenza Vaccine (30 μg/strain) or of placebo will be administered to approximately 10,000 participants
Eligibility Criteria
Inclusion Criteria
Participants must meet all of the following inclusion criteria to be eligible for participation in this study; no protocol waivers are allowed:
- Participants must have a body mass index (BMI) below 40 kg/m^2;
- Participants are considered by the Investigator to be reliable and likely to cooperate with the assessment procedures and be available for the duration of the study;
- Participants must be in good general health prior to study participation, with no clinically relevant abnormalities that could jeopardize participant safety or interfere with study assessments, as assessed by the Principal Investigator or sub-Investigator (thereafter referred as Investigator) and determined by medical history, physical examination, and vital signs; Note: Participants with a pre-existing chronic disease will be allowed to participate if the disease is stable and, according to the Investigator's judgment, the condition is unlikely to confound the results of the study or pose additional risk to the participant by participating in the study. Stable disease is generally defined as no new onset or exacerbation of pre-existing chronic disease three months prior to vaccination. Based on the Investigator's judgment, a participant with more recent stabilization of a disease could also be eligible.
- Female participants must have a negative urine pregnancy test result at the Screening/Vaccination visit (Visit 1).
- Female participants of childbearing potential must use an effective method of contraception for one month prior to vaccination and agree to continue employing adequate birth control measures for at least 60 days post-vaccination. Moreover, female participants must have no plan to become pregnant for at least two months post-vaccination. Abstinent participants should be asked what method(s) they would use should their circumstances change, and participants without a well-defined plan should be excluded. The following relationship or methods of contraception are considered to be effective:
- Hormonal contraceptives (e.g. oral, injectable, topical [patch], or estrogenic vaginal ring);
- Intra-uterine device with or without hormonal release;
- Male partner using a condom plus spermicide or sterilized partner (at least one year prior to vaccination);
- Credible self-reported history of heterosexual vaginal intercourse abstinence until at least 60 days post-vaccination;
- Female partner;
- Non-childbearing females are defined as:
- Surgically-sterile (defined as bilateral tubal ligation, hysterectomy or bilateral oophorectomy performed more than one month prior to vaccination); or
- Post-menopausal (absence of menses for 24 consecutive months and age consistent with natural cessation of ovulation).
Exclusion Criteria
Participants who meet any of the following criteria will be excluded from participating in this study; no protocol waivers are allowed:
- Any participant whose medical condition(s) is sufficiently severe that annual influenza vaccination would be routinely recommended in the jurisdiction of recruitment, as per the Investigator's judgement;
- According to the Investigator's opinion, history of significant acute or chronic, uncontrolled medical or neuropsychiatric illness. 'Uncontrolled' is defined as:
- Requiring a new medical or surgical treatment during the three months prior to study vaccine administration unless the criteria outlined in inclusion criterion no. 5 can be met (i.e. the Investigator can justify inclusion based upon the innocuous nature of medical/surgical events and/or treatments);
- Requiring any significant change in a chronic medication (i.e. drug, dose, frequency) during the three months prior to study vaccine administration due to uncontrolled symptoms or drug toxicity unless the innocuous nature of the medication change meets the criteria outlined in inclusion criterion no. 5 and is appropriately justified by the Investigator.
- Any medical or neuropsychiatric condition or
Data sourced from ClinicalTrials.gov (NCT03301051). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.